{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:07:59Z","timestamp":1772892479583,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bristol Myers Squibb"},{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020957","name":"Roche Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00415-025-13330-7","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:05:15Z","timestamp":1756973115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-5025","authenticated-orcid":false,"given":"David","family":"Ellenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-774X","authenticated-orcid":false,"given":"Niklas","family":"Frahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-105X","authenticated-orcid":false,"given":"Alexander","family":"Stahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9255","authenticated-orcid":false,"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-5339","authenticated-orcid":false,"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Flachenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-9096","authenticated-orcid":false,"given":"Michaela","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7998-5310","authenticated-orcid":false,"given":"Matthias","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"13330_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391:1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"},{"key":"13330_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325:765\u2013779. https:\/\/doi.org\/10.1001\/jama.2020.26858","journal-title":"JAMA"},{"key":"13330_CR3","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/biom11101510","volume":"11","author":"M Hecker","year":"2021","unstructured":"Hecker M, B\u00fchring J, Fitzner B et al (2021) Genetic, environmental and lifestyle determinants of accelerated telomere attrition as contributors to risk and severity of multiple sclerosis. Biomolecules 11:1510. https:\/\/doi.org\/10.3390\/biom11101510","journal-title":"Biomolecules"},{"key":"13330_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","volume":"22","author":"JS Graves","year":"2023","unstructured":"Graves JS, Krysko KM, Hua LH et al (2023) Ageing and multiple sclerosis. Lancet Neurol 22:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(22)00184-3","journal-title":"Lancet Neurol"},{"key":"13330_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001094","volume":"8","author":"M Eschborn","year":"2021","unstructured":"Eschborn M, Pawlitzki M, Wirth T et al (2021) Evaluation of age-dependent immune signatures in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8:e1094. https:\/\/doi.org\/10.1212\/NXI.0000000000001094","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13330_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","volume":"22","author":"SA Sanai","year":"2016","unstructured":"Sanai SA, Saini V, Benedict RH et al (2016) Aging and multiple sclerosis. Mult Scler 22:717\u2013725. https:\/\/doi.org\/10.1177\/1352458516634871","journal-title":"Mult Scler"},{"key":"13330_CR7","doi-asserted-by":"publisher","first-page":"1379538","DOI":"10.3389\/fimmu.2024.1379538","volume":"15","author":"\u00d3 Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez \u00d3, S\u00f6rensen PS, Comi G et al (2024) Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review. Front Immunol 15:1379538. https:\/\/doi.org\/10.3389\/fimmu.2024.1379538","journal-title":"Front Immunol"},{"key":"13330_CR8","doi-asserted-by":"publisher","first-page":"175628642110396","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T et al (2021) Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 14:17562864211039648. https:\/\/doi.org\/10.1177\/17562864211039648","journal-title":"Ther Adv Neurol Disord"},{"key":"13330_CR9","doi-asserted-by":"publisher","first-page":"175628642412397","DOI":"10.1177\/17562864241239740","volume":"17","author":"N Frahm","year":"2024","unstructured":"Frahm N, Ellenberger D, Stahmann A et al (2024) Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry. Ther Adv Neurol Disord 17:17562864241239740. https:\/\/doi.org\/10.1177\/17562864241239740","journal-title":"Ther Adv Neurol Disord"},{"key":"13330_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16289","volume":"31","author":"EC Tallantyre","year":"2024","unstructured":"Tallantyre EC, Dobson R, Froud JLJ et al (2024) Real-world persistence of multiple sclerosis disease-modifying therapies. Eur J Neurol 31:e16289. https:\/\/doi.org\/10.1111\/ene.16289","journal-title":"Eur J Neurol"},{"key":"13330_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231198588","volume":"9","author":"H Tumani","year":"2023","unstructured":"Tumani H, Coyle PK, C\u00e1rcamo C et al (2023) Treatment of older patients with multiple sclerosis: results of an international delphi survey. Mult Scler 9:20552173231198588. https:\/\/doi.org\/10.1177\/20552173231198588","journal-title":"Mult Scler"},{"key":"13330_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2741\/4889","volume":"26","author":"S Tabibzadeh","year":"2021","unstructured":"Tabibzadeh S (2021) Signaling pathways and effectors of aging. Front Biosci (Landmark Ed) 26:50\u201396. https:\/\/doi.org\/10.2741\/4889","journal-title":"Front Biosci (Landmark Ed)"},{"key":"13330_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2021.732414","volume":"2","author":"AL Thomas","year":"2021","unstructured":"Thomas AL, Alarcon PC, Divanovic S et al (2021) Implications of inflammatory states on dysfunctional immune responses in aging and obesity. Front Aging 2:732414. https:\/\/doi.org\/10.3389\/fragi.2021.732414","journal-title":"Front Aging"},{"key":"13330_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K et al (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 8:577. https:\/\/doi.org\/10.3389\/fneur.2017.00577","journal-title":"Front Neurol"},{"key":"13330_CR15","doi-asserted-by":"publisher","first-page":"e1322","DOI":"10.1212\/WNL.0000000000012610","volume":"97","author":"R Palladino","year":"2021","unstructured":"Palladino R, Chataway J, Majeed A, Marrie RA (2021) Interface of multiple sclerosis, depression, vascular disease, and mortality: a population-based matched cohort study. Neurology 97:e1322\u2013e1333. https:\/\/doi.org\/10.1212\/WNL.0000000000012610","journal-title":"Neurology"},{"key":"13330_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/13524585241272938","volume":"30","author":"EM Coerver","year":"2024","unstructured":"Coerver EM, Ka\u00e7ar S, Ciccarelli O et al (2024) Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations. Mult Scler 30:1296\u20131308. https:\/\/doi.org\/10.1177\/13524585241272938","journal-title":"Mult Scler"},{"key":"13330_CR17","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00415-020-09895-0","volume":"267","author":"MW Koch","year":"2020","unstructured":"Koch MW, Mostert J, Greenfield J et al (2020) Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. J Neurol 267:2619\u20132624. https:\/\/doi.org\/10.1007\/s00415-020-09895-0","journal-title":"J Neurol"},{"key":"13330_CR18","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","volume":"271","author":"KA DiMauro","year":"2024","unstructured":"DiMauro KA, Swetlik C, Cohen JA (2024) Management of multiple sclerosis in older adults: review of current evidence and future perspectives. J Neurol 271:3794\u20133805. https:\/\/doi.org\/10.1007\/s00415-024-12384-3","journal-title":"J Neurol"},{"key":"13330_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","volume":"37","author":"L Prosperini","year":"2023","unstructured":"Prosperini L, Haggiag S, Ruggieri S et al (2023) Stopping disease-modifying treatments in multiple sclerosis: a systematic review and meta-analysis of real-world studies. CNS Drugs 37:915\u2013927. https:\/\/doi.org\/10.1007\/s40263-023-01038-z","journal-title":"CNS Drugs"},{"key":"13330_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-023-12041-1","volume":"271","author":"A Zinganell","year":"2024","unstructured":"Zinganell A, G\u00f6bel G, Berek K et al (2024) Multiple sclerosis in the elderly: a retrospective cohort study. J Neurol 271:674\u2013687. https:\/\/doi.org\/10.1007\/s00415-023-12041-1","journal-title":"J Neurol"},{"key":"13330_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209574","volume":"103","author":"S Pfeuffer","year":"2024","unstructured":"Pfeuffer S, Wolff S, Aslan D et al (2024) Association of clinical relapses with disease outcomes in multiple sclerosis patients older than 50 years. Neurology 103:e209574. https:\/\/doi.org\/10.1212\/WNL.0000000000209574","journal-title":"Neurology"},{"key":"13330_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I et al (2023) Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 22:568\u2013577. https:\/\/doi.org\/10.1016\/S1474-4422(23)00154-0","journal-title":"Lancet Neurol"},{"key":"13330_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40120-021-00320-w","volume":"11","author":"N Frahm","year":"2022","unstructured":"Frahm N, Fneish F, Ellenberger D et al (2022) Therapy switches in fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS registry. Neurol Ther 11:319\u2013336. https:\/\/doi.org\/10.1007\/s40120-021-00320-w","journal-title":"Neurol Ther"},{"key":"13330_CR24","doi-asserted-by":"publisher","first-page":"13340","DOI":"10.1038\/s41598-021-92722-x","volume":"11","author":"L-M Ohle","year":"2021","unstructured":"Ohle L-M, Ellenberger D, Flachenecker P et al (2021) Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. Sci Rep 11:13340. https:\/\/doi.org\/10.1038\/s41598-021-92722-x","journal-title":"Sci Rep"},{"key":"13330_CR25","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00415-024-12286-4","volume":"271","author":"Y Goereci","year":"2024","unstructured":"Goereci Y, Ellenberger D, Rommer P et al (2024) Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry. J Neurol 271:3409\u20133416. https:\/\/doi.org\/10.1007\/s00415-024-12286-4","journal-title":"J Neurol"},{"key":"13330_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","volume":"81","author":"G Jouvenot","year":"2024","unstructured":"Jouvenot G, Courbon G, Lefort M et al (2024) High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol 81:490\u2013498. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0395","journal-title":"JAMA Neurol"},{"key":"13330_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104935","volume":"79","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L et al (2023) Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina. Mult Scler Relat Disord 79:104935. https:\/\/doi.org\/10.1016\/j.msard.2023.104935","journal-title":"Mult Scler Relat Disord"},{"key":"13330_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/PPA.S509525","volume":"19","author":"FJ Barrero Hern\u00e1ndez","year":"2025","unstructured":"Barrero Hern\u00e1ndez FJ, Morales Lahoz \u00c1J, Serrano Guti\u00e9rrez C et al (2025) Clinical practice evidence of treatment satisfaction with moderate and high-efficacy drugs in multiple sclerosis. Patient Prefer Adherence 19:715\u2013727. https:\/\/doi.org\/10.2147\/PPA.S509525","journal-title":"Patient Prefer Adherence"},{"key":"13330_CR29","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","volume":"95","author":"MD Buron","year":"2020","unstructured":"Buron MD, Chalmer TA, Sellebjerg F et al (2020) Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology 95:e1041\u2013e1051. https:\/\/doi.org\/10.1212\/WNL.0000000000010135","journal-title":"Neurology"},{"key":"13330_CR30","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269:5382\u20135394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w","journal-title":"J Neurol"},{"key":"13330_CR31","unstructured":"European Medicines Agency (2018) Ocrevus. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Accessed 4 August 2025"},{"key":"13330_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/13524585241261565","volume":"30","author":"M Zeineddine","year":"2024","unstructured":"Zeineddine M, Al-Roughani R, Farouk Ahmed S et al (2024) Safety and effectiveness of disease-modifying therapies after switching from natalizumab. Mult Scler 30:1026\u20131035. https:\/\/doi.org\/10.1177\/13524585241261565","journal-title":"Mult Scler"},{"key":"13330_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/13524585221122207","volume":"29","author":"A Chertcoff","year":"2023","unstructured":"Chertcoff A, Ng HS, Zhu F et al (2023) Polypharmacy and multiple sclerosis: a population-based study. Mult Scler 29:107\u2013118. https:\/\/doi.org\/10.1177\/13524585221122207","journal-title":"Mult Scler"},{"key":"13330_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221108391","volume":"13","author":"JL Debus","year":"2022","unstructured":"Debus JL, Bachmann P, Frahm N et al (2022) Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis. Ther Adv Chronic Dis 13:20406223221108391. https:\/\/doi.org\/10.1177\/20406223221108391","journal-title":"Ther Adv Chronic Dis"},{"key":"13330_CR35","doi-asserted-by":"publisher","first-page":"175628642096950","DOI":"10.1177\/1756286420969501","volume":"13","author":"N Frahm","year":"2020","unstructured":"Frahm N, Hecker M, Langhorst SE et al (2020) The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis. Ther Adv Neurol Disord 13:1756286420969501. https:\/\/doi.org\/10.1177\/1756286420969501","journal-title":"Ther Adv Neurol Disord"},{"key":"13330_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1446944","volume":"19","author":"PS Rommer","year":"2018","unstructured":"Rommer PS, Zettl UK (2018) Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 19:483\u2013498. https:\/\/doi.org\/10.1080\/14656566.2018.1446944","journal-title":"Expert Opin Pharmacother"},{"key":"13330_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102815","volume":"50","author":"A Ostolaza","year":"2021","unstructured":"Ostolaza A, Corroza J, Ayuso T (2021) Multiple sclerosis and aging: comorbidity and treatment challenges. Mult Scler Relat Disord 50:102815. https:\/\/doi.org\/10.1016\/j.msard.2021.102815","journal-title":"Mult Scler Relat Disord"},{"issue":"Suppl 6","key":"13330_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00415-008-6016-8","volume":"255","author":"T Klauer","year":"2008","unstructured":"Klauer T, Zettl UK (2008) Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 255(Suppl 6):87\u201392. https:\/\/doi.org\/10.1007\/s00415-008-6016-8","journal-title":"J Neurol"},{"key":"13330_CR39","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.27034","volume":"96","author":"A Scalfari","year":"2024","unstructured":"Scalfari A, Traboulsee A, Oh J et al (2024) Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions. Ann Neurol 96:826\u2013845. https:\/\/doi.org\/10.1002\/ana.27034","journal-title":"Ann Neurol"},{"key":"13330_CR40","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/1352458520964778","volume":"27","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Haggiag S, Tortorella C et al (2021) Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler 27:1391\u20131402. https:\/\/doi.org\/10.1177\/1352458520964778","journal-title":"Mult Scler"},{"key":"13330_CR41","doi-asserted-by":"publisher","first-page":"1197195","DOI":"10.3389\/fimmu.2023.1197195","volume":"14","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, Fisk JD, Fitzgerald K et al (2023) Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Front Immunol 14:1197195. https:\/\/doi.org\/10.3389\/fimmu.2023.1197195","journal-title":"Front Immunol"},{"key":"13330_CR42","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147\u20133161. https:\/\/doi.org\/10.1093\/brain\/awac016","journal-title":"Brain"},{"key":"13330_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1 et al (2023) Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 80:151\u2013160. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4655","journal-title":"JAMA Neurol"},{"key":"13330_CR44","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J et al (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80:1232\u20131245. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13330-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:21Z","timestamp":1760524521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13330-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13330"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13330-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.E. had no personal financial interests to disclose other than being an employee of the GMSR. N.F. is an employee of the GMSR. Moreover, he is an employee of Rostock\u2019s University Medical Center and received travel funds for research meetings from Novartis. None resulted in a conflict of interest. A.S. has no personal pecuniary interests to disclose, other than being the lead of the German MS Registry, which receives (project) funding from a range of public and corporate sponsors, recently including The German Innovation Fund (G-BA), The German Retirement Insurance, The German MS Trust, The German MS Society, Bristol Myers Squibb, Merck Healthcare Germany GmbH, Novartis Pharma GmbH, Roche Pharma AG and TG Therapeutics\/Neuraxpharm. None resulted in a conflict of interest. C.W. has received institutional support from Novartis, Alexion, Sanofi Genzyme, Biogen, Merck, and Roche. None resulted in a conflict of interest. K.H. has received speaking fees and\/or institutional grant support from Bayer, Biogen, BMS, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. None resulted in a conflict of interest. D.K. has nothing to disclose. C.K. has received speaker\u2019s fees, honoraria for attending advisory boards, and financial support for conducting research projects from Merck Serono GmbH Germany, and Merck KgaA Germany. None resulted in a conflict of interest. P.F. has received speaker\u2019s fees and honoraria for advisory boards from Almirall, Bayer, Biogen Idec, BMS-Celgene, Coloplast, Genzyme, GW Pharma, Hexal, Janssen-Cilag, Novartis, Merck, Roche, Sanofi, Stadapharm, and Teva. None resulted in a conflict of interest. M.M. is an employee of the German MS Society, federal association, which receives funding from a range of public and corporate sponsors, recently including BMG, G-BA, The German MS Trust, Biogen, BMS, Merck Serono, Novartis, Roche, Sanofi, and Viatris. None resulted in a conflict of interest. M.G. received honoraria and travel reimbursements for attending meetings from Biogen, Celgene, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Merck Serono, and Novartis. None resulted in a conflict of interest. U.K.Z. has received speaking fees, travel support and \/or financial support for research activities from Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb, Janssen, Merck Serono, Novartis, Octapharma, Roche, Sanofi Genzyme, Teva as well as EU, BMBF, BMWi, and DFG. None resulted in a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The registration of the GMSR took place at the German Registry for Clinical Trials [Deutsches Register Klinischer Studien (DRKS); No. DRKS00011257]. The initial ethics vote was approved by University of W\u00fcrzburg\u2019s institutional review board (Permit No. 142\/12). All participants provided written consent for the utilization of their anonymized data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}}],"article-number":"609"}}